Dr. Magee on use of exogenous testosterone in patients with localized prostate cancer

“Perspectives on testosterone therapy and its use as it pertains to prostate cancer have certainly progressed over [the] years,” Diana Magee, MD, MPH, MSc.

In this video, Diana Magee, MD, MPH, MSc, summarizes the 2022 Society of Urologic Oncology Annual Meeting presentation, “Use of exogenous testosterone in the setting of screening, active surveillance, and after treatment of localized disease.” Magee is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania.